These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

882 related articles for article (PubMed ID: 9033462)

  • 1. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
    Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
    Olsen SL; Gilbert EM; Renlund DG; Taylor DO; Yanowitz FD; Bristow MR
    J Am Coll Cardiol; 1995 May; 25(6):1225-31. PubMed ID: 7722114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Doughty RN; Whalley GA; Gamble G; MacMahon S; Sharpe N
    J Am Coll Cardiol; 1997 Apr; 29(5):1060-6. PubMed ID: 9120160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
    Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
    Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
    Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH
    N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure.
    Macdonald PS; Keogh AM; Aboyoun CL; Lund M; Amor R; McCaffrey DJ
    J Am Coll Cardiol; 1999 Mar; 33(4):924-31. PubMed ID: 10091817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Doughty RN; Whalley GA; Gamble G; MacMahon S; Sharpe N
    J Card Fail; 2000 Mar; 6(1):11-8. PubMed ID: 10746814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure.
    Razzolini R; Tarantini G; Boffa GM; Orlando S; Iliceto S
    Ital Heart J; 2004 Jul; 5(7):517-22. PubMed ID: 15487269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy.
    Quaife RA; Gilbert EM; Christian PE; Datz FL; Mealey PC; Volkman K; Olsen SL; Bristow MR
    Am J Cardiol; 1996 Oct; 78(7):779-84. PubMed ID: 8857482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effects of mid- and long-term administration (3-4 years) of carvedilol in patients with idiopathic dilated cardiomyopathy].
    Metra M; Nodari S; Garbellini M; Boldi E; Rosselli F; Milan E; Giubbini R; Dei Cas L
    Cardiologia; 1997 May; 42(5):503-12. PubMed ID: 9289367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Landmark studies: the Australia/New Zealand Heart Failure Collaborative Group (ANZ) Trial and the US Carvedilol Trials Program.
    Gilbert EM
    Am J Cardiol; 2004 May; 93(9A):30B-4B. PubMed ID: 15144934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation.
    Khand AU; Chew PG; Douglas H; Jones J; Jan A; Cleland JG
    Cardiology; 2015; 130(3):153-8. PubMed ID: 25660493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
    Capomolla S; Febo O; Gnemmi M; Riccardi G; Opasich C; Caporotondi A; Mortara A; Pinna GD; Cobelli F
    Am Heart J; 2000 Apr; 139(4):596-608. PubMed ID: 10740140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function.
    Lombardo RM; Reina C; Abrignani MG; Rizzo PA; Braschi A; De Castro S
    Am J Cardiovasc Drugs; 2006; 6(4):259-63. PubMed ID: 16913827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial).
    Figulla HR; Krzeminska-Pakula M; Wrabec K; Chochola J; Kalmbach C; Fridl P
    Int J Cardiol; 2006 Nov; 113(2):153-60. PubMed ID: 16157399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of carvedilol on survival in severe chronic heart failure.
    Packer M; Coats AJ; Fowler MB; Katus HA; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Roecker EB; Schultz MK; DeMets DL;
    N Engl J Med; 2001 May; 344(22):1651-8. PubMed ID: 11386263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.
    Cohn JN; Fowler MB; Bristow MR; Colucci WS; Gilbert EM; Kinhal V; Krueger SK; Lejemtel T; Narahara KA; Packer M; Young ST; Holcslaw TL; Lukas MA
    J Card Fail; 1997 Sep; 3(3):173-9. PubMed ID: 9330125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.